查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
克拉培氏病治療的全球市場(2022年～2029年)
市場調查報告書
商品編碼
1082813

克拉培氏病治療的全球市場(2022年～2029年)

Global Krabbe Disease Treatment Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

本報告提供全球克拉培氏病治療調查分析，市場概要，以及市場趨勢，推動及阻礙市場要素，COVID-19影響，產業分析，各市場區隔、各地區的市場分析，競爭情形，企業簡介等資訊。

目錄

第1章 全球克拉培氏病治療市場:範圍調查手法

  • 調查手法
  • 調查的目的和調查範圍

第2章 全球克拉培氏病治療市場:市場定義和概要

第3章 全球克拉培氏病治療市場:摘要整理

  • 各疾病類型的市場明細
  • 各診斷市場明細
  • 各治療市場明細
  • 各終端用戶市場明細
  • 各流通管道的市場明細
  • 各地區的市場明細

第4章 全球克拉培氏病治療市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素:
    • 市場機會
    • 影響分析

第5章 全球克拉培氏病治療市場:產業分析

  • 供應鏈分析
  • 價格分析
  • 未滿足需求

第6章 全球克拉培氏病治療市場:COVID-19分析

  • 市場的COVID-19影響分析
    • COVID-19前的市場情境
    • COVID-19目前市場情境
    • COVID-19後或未來情境
  • COVID-19的價格變動
  • 需求與供給的頻譜
  • 大流行時的市場相關的政府的配合措施
  • 製造商策略性配合措施
  • 結論

第7章 全球克拉培氏病治療市場:各疾病類型

  • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場魅力指數:各疾病類型
  • 嬰幼期
    • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
  • 遲發性

第8章 全球克拉培氏病治療市場:各診斷

  • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場魅力指數:各診斷
  • 臨床檢驗
    • 血液檢驗
    • 其他
    • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
  • 影像檢查
    • 核磁共振影像(MRI)
    • 電腦斷層攝影(CT)
    • 其他
  • 遺傳基因檢驗
  • 新生兒篩檢
  • 其他

第9章 全球克拉培氏病治療市場:各治療

  • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場魅力指數:各治療
  • 抗痙攣藥
    • Acetazolamide
    • Carbamazepine
    • Tegretol
    • Clobazam
    • Gabapentin
    • 其他
    • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
  • 肌肉鬆弛劑
    • Tizanidine
    • Carisoprodol
    • Chlorzoxazone
    • Metaxalone
    • 其他
  • 骨髓移植
  • 幹細胞移植
  • 其他

第10章 全球克拉培氏病治療市場:各終端用戶

  • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場魅力指數:各終端用戶
  • 醫院
    • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
  • 診斷中心
  • 診所
  • 其他

第11章 全球克拉培氏病治療市場:各流通管道

  • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場魅力指數:各流通管道
  • 醫院藥局
    • 簡介
    • 市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
  • 零售藥局
  • 線上藥局
  • 其他

第12章 全球克拉培氏病治療市場:各地區

  • 簡介
    • 各地區的市場規模分析、與前一年同期比較成長分析(%):2020年～2029年，及2021年～2029年(百萬美元)
    • 各地區的市場魅力指數
  • 北美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析、與前一年同期比較成長分析(%):各國
  • 歐洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析、與前一年同期比較成長分析(%):各國
  • 南美
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析、與前一年同期比較成長分析(%):各國
  • 亞太地區
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道
    • 市場規模分析、與前一年同期比較成長分析(%):各國
  • 中東和非洲
    • 簡介
    • 主要地區具體動態
    • 市場規模分析、與前一年同期比較成長分析(%):各疾病類型
    • 市場規模分析、與前一年同期比較成長分析(%):各診斷
    • 市場規模分析、與前一年同期比較成長分析(%):各治療
    • 市場規模分析、與前一年同期比較成長分析(%):各終端用戶
    • 市場規模分析、與前一年同期比較成長分析(%):各流通管道

第13章 競爭情形

  • 主要的發展與策略
  • 企業佔有率分析
  • 產品的基準
  • 值得注意的主要企業的清單

第14章 企業簡介

  • Lannett
    • 企業概要
    • 產品系列、說明
    • 主要亮點
    • 財務概要
  • Novartis
  • Lundbeck
  • Lupin Pharmaceuticals, Inc.
  • Teva Pharmaceuticals USA, Inc.
  • Meda Pharmaceuticals Inc
  • Mayne Pharma Group Limited
  • Pfizer Inc.
  • Schwarz Pharma, Inc
  • Acorda Therapeutics Inc.

第15章 全球克拉培氏病治療市場:DataM

簡介目錄
Product Code: DMPH5230

Market Overview

The global krabbe disease treatment market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of XX % during the forecast period (2022-2029).

Krabbe disease is a life-threatening neurological disorder commonly known as globoid cell leukodystrophy. It is one of a series of conditions known as leukodystrophies, caused by the breakdown of myelin in the nervous system (demyelination). Myelin is the protective layer that surrounds nerve cells and ensures that nerve signals are transmitted quickly. Krabbe illness is also characterized by aberrant brain cells known as globoid cells, huge cells with more than one nucleus. Krabbe disease is identified in children as young as six years old, and there is presently no cure; nevertheless, the condition is controlled by supportive care.

Market Dynamics

Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.

Other experimental medicines have demonstrated varying degrees of effectiveness in preclinical testing, with some of the best results from combining medications. For instance, HSCT has been used with SRT and gene therapy. The combinations consistently yield better outcomes than the matched individual therapies. Other approaches such as ERT, chaperone therapy, and anti-inflammatory therapy also have the potential to contribute as part of a combination or standalone therapies. Moreover, various clinical studies have been carried out. For instance, D-Cycloserine is an FDA-approved medicine for tuberculosis tested in numerous clinical studies for various diseases. Preliminary data suggest that it can slow disease progression in twitcher mice; consequently, D-cycloserine should be studied further to see if it can help individuals with Krabbe disease. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

The finite patient pool for clinical trials, lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. The risk of severe forms of COVID-19 may be high in the rare metabolic community, where all patients, including children, experience multiorgan impairments due to their chronic condition. MetabERN, the European Reference Network for Hereditary Metabolic Diseases, conducted two surveys: one for patients' organizations (PO) and the other for healthcare providers (HCPs). COVID-19 incidence was lower in the community of uncommon metabolic patients (72.9 per 100,000 vs. 117 per 100,000) than in the general European population. On the other hand, patients were subjected to significant disruptions in their care, with most appointments and treatments being canceled, curtailed, or postponed. Almost all HCPs (90 percent) used telemedicine to replace face-to-face visits, about half of patients undergoing treatment changes switched from hospital to home therapy, and a quarter of patients had difficulty getting their medications.

Additionally, the pandemic interrupts the supply chain and process. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Stem cell transplantation segment is expected to hold the largest market share in krabbe disease treatment market

The stem cell transplantation segment is expected to dominate in 2021. The segment benefits because if treatment begins before the development of symptoms, that is, when a diagnosis is made via a newborn screening test, this therapy may improve outcomes in newborns. According to current evidence, stem cell transplantation is most beneficial when initiated before a newborn reaches the age of two weeks. Moreover, Pre-symptomatic children who have stem cell transplantation had a slower disease progression and a better quality - and duration - of life than children who do not receive stem cell transplantation before symptoms arise, according to studies. Furthermore, This medication may also benefit older children and adults with modest Krabbe disease symptoms. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global krabbe disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of Krabbe Disease, rising geriatric population, Rapid adoption of cutting-edge technologies and novel medications for the treatment of Krabbe illness, well-established infrastructure and increase in clinical development of the treatment for the Krabbe disease, and rise in investment in research & development are some of the factors the market is expected to boost in the forecast period. For instance, the Krabbe disease affects about 1 in 100,000 people in the United States. It is also known as globoid cell leukodystrophy. Males are affected as often as females.

Also, more than two-fifths of all known cases of Krabbe disease is caused by a missense mutation in the GLC enzyme. Therapeutic approaches for other lysosomal storage diseases are ineffective in treating Krabbe disease due to the lack of accumulated primary substrate within the lysosome and the predominant CNS sickness. The molecules are being researched because they have the potential to pass the blood-brain barrier more efficiently than enzymes due to certain properties such as low molecular weight, low toxicity, and high bioavailability. Allosteric chaperones, directed away from the enzyme's active site, have also been found. Pharmacological chaperone therapy, which is expected to be effective, can be used to treat Krabbe disease. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the krabbe disease treatment market are Lannett, Novartis, Lundbeck, Lupin Pharmaceuticals, Inc., Teva Pharmaceuticals USA, Inc., Meda Pharmaceuticals Inc , Mayne Pharma Group Limited, Pfizer Inc., Schwarz Pharma, Inc, Acorda Therapeutics Inc.

Pfizer Inc.:

Overview:

Pfizer Inc. is an American multinational pharmaceutical company that offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. It has a portfolio of over 150 products across 15 therapeutic areas. The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, endocrinology, and neurology.

­Product Portfolio:

SKELAXIN(metaxalone): Metaxalone is a muscle relaxant. It works by blocking nerve impulses (or pain sensations) in the brain. It is used with rest and physical therapy to treat skeletal muscle conditions such as pain or injury.

Why Purchase the Report?

Visualize the composition of the krabbe disease treatment market segmentation by disease type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in krabbe disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of krabbe disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global krabbe disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Disease Type
  • 3.2. Market Snippet by Diagnosis
  • 3.3. Market Snippet by Treatment
  • 3.4. Market Snippet by End user
  • 3.5. Market Snippet by Distribution channel
  • 3.6. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Advancement in the therapies for the treatment of Krabbe Disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of the disease and side effects of the drugs are factors the market is expected to hamper in the forecast period.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type Segment
  • 7.2. Infantile*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Late-onset

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis Segment
  • 8.2. Laboratory tests*
    • 8.2.1. Blood Test
    • 8.2.2. Others
    • 8.2.3. Introduction
    • 8.2.4. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Imaging tests
    • 8.3.1. Magnetic resonance imaging (MRI)
    • 8.3.2. Computerized tomography (CT)
    • 8.3.3. Others
  • 8.4. Genetic testing
  • 8.5. Newborn screening
  • 8.6. Others

9. By Treatment

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 9.1.2. Market Attractiveness Index, By Treatment Segment
  • 9.2. Anticonvulsant Agents*
    • 9.2.1. Acetazolamide
    • 9.2.2. Carbamazepine
    • 9.2.3. Tegretol
    • 9.2.4. Clobazam
    • 9.2.5. Gabapentin
    • 9.2.6. Others
    • 9.2.7. Introduction
    • 9.2.8. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Muscle Relaxer Drugs
    • 9.3.1. Tizanidine
    • 9.3.2. Carisoprodol
    • 9.3.3. Chlorzoxazone
    • 9.3.4. Metaxalone
    • 9.3.5. Others
  • 9.4. Bone Marrow Transplantation
  • 9.5. Stem cell transplantation
  • 9.6. Others

10. By End user

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 10.1.2. Market Attractiveness Index, By End user Segment
  • 10.2. Hospitals*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 10.3. Diagnostic Centers
  • 10.4. Clinics
  • 10.5. Others

11. By Distribution Channel

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 11.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 11.2. Hospital Pharmacies*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 11.3. Retail Pharmacies
  • 11.4. Online Pharmacies
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.2.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. U.K.
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.8. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 12.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
    • 12.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
    • 12.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

13. Competitive Landscape

  • 13.1. Key Developments and Strategies
  • 13.2. Company Share Analysis
  • 13.3. Product Benchmarking
  • 13.4. List of Key Companies to Watch

14. Company Profiles

  • 14.1. Lannett*
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Key Highlights
    • 14.1.4. Financial Overview
  • 14.2. Novartis
  • 14.3. Lundbeck
  • 14.4. Lupin Pharmaceuticals, Inc.
  • 14.5. Teva Pharmaceuticals USA, Inc.
  • 14.6. Meda Pharmaceuticals Inc
  • 14.7. Mayne Pharma Group Limited
  • 14.8. Pfizer Inc.
  • 14.9. Schwarz Pharma, Inc
  • 14.10. Acorda Therapeutics Inc.

LIST NOT EXHAUSTIVE

15. Global Krabbe Disease Treatment Market - DataM

  • 15.1. Appendix
  • 15.2. About Us and Applications
  • 15.3. Contact Us